Citations

Clear

63 citation(s) found for "Anderson, Jennifer".

Exome Sequencing Enhances Screening for Familial Hypercholesterolemia Within a Multi-Site Healthcare System
Samadder, N. Jewel , Schroeder, Mariah , Petersen, M. , Shamoun, Fadi , Kullo, Iftikhar J. , Curry, Timothy B. , Houwink, Elisa J. F. , Bublitz, Michelle L. , Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Olson, Rory J. , Tan-Arroyo, Jennifer , Morales‐Rosado, Joel A. , Klee, Eric W. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa , Anderson, Jennifer L. , McAllister, Tammy M., Baudhuin, Linnea M. , Summer-Bolster, Jolene M., Voss, Molly M , Kullo, Iftikhar J , Vierkant, Robert A , Ferber, Matthew J , Olson, Rory , Arroyo, Jennifer , Morales-Rosado, Joel A , Klee, Eric W , Larson, Nicholas B , Kruisselbrink, Teresa M , Egan, Jan B , Bidwell, Jessa S , Baudhuin, Linnea M , Kunze, Katie L , Golafshar, Michael , Presutti, Richard J , Lazaridis, Konstantinos N , Houwink, Elisa J F , Schroeder, Mariah L , Vierkant, Robert A. , Larson, Nicholas B. , Kunze, Katie L. , Golafshar, Michael A. , Presutti, R. John , Lazaridis, Konstantinos N.

Mayo Clinic

Circulation: Genomic and Precision Medicine | November 12, 2025 | Volume: 18 | Issue: 6 | Pages: No page available

10.1161/circgen.125.005174 | PMID 41221644 Get It

BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that increases risk for premature coronary artery disease and has accessible and effective interventions. The Dutch lipid clinic network is currently the most used diagnostic criterion; however, genetic sequencing provides a definitive diagnosis of FH. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify individuals who were genotype positive for FH. METHODS: Participants were recruited from 3 geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; and Jacksonville, FL). Participants underwent Exome+ sequencing (dba Helix, San Mateo, CA) and return of results for specific genetic findings in APOB , LDLR , or PCSK9 . A chart review was performed to collect demographics, personal, and family cardiovascular history. RESULTS: At the time of the study, 84 413 participants were enrolled in the Tapestry study. Annotation and interpretation of all variants in genes for FH resulted in the identification of 419 likely pathogenic and pathogenic variants (prevalence, 0.50%), which included 116 APOB , 298 LDLR , and 5 PCSK9 . Sixty-six percent were female, the mean body mass index was 27.3, with 12.3% reporting a history of diabetes. Hypertriglyceridemia (≥150 mg/dL) was present in 39.5% and reduced HDL (<50 mg/dL) was present in 56.7% of patients. 27.5% of patients were not on cholesterol-lowering medications, and only 10% of FH carriers were at goal low-density lipoprotein cholesterol levels. A history of coronary artery disease was reported in 22.4% of the cohort. Nearly 90% of these participants were newly diagnosed carriers of FH. Only 30.8% of confirmed genetic diagnoses of FH satisfied clinical (Dutch lipid clinic network) criteria for a diagnosis. CONCLUSIONS: Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have familial hypercholesterolemia. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05212428.
MON-011 Presentation, Management and Outcomes of Ectopic ACTH Syndrome: an International Multicenter Retrospective Study
Chacko, Shireen R , Torres, Camila A Villavicencio, Lü, Lin , Bandgar, Tushar, Varlamov, Elena V , Paissan, Andrea, Imamudeen, Nasvin, Tabarin, Antoine, Shah, Rutu, Peersen, Anina, Kaplan, Jennifer B. , Varghese, Jeena , Yamichannaiah, Chethan, Yu, Kai , Waguespack, Steven G. , Belaya, Zhanna E. , Bandgar, Tushar , Sada, Alaa , Ragnarsson, Oskar , Altieri, Barbara , Newman, Andrew J , Vibhatavata, Peeradon , Tóth, Miklós , Badiu, Corin , St‐Jean, Matthieu , Falhammar, Henrik , Haberbosch, Linus , Bobrowicz, Małgorzata , Gadelha, Mônica R. , Young, William F. , Kaplan, Jennifer, Habra, Mouhammed Amir , Golounina, Olga O. , Mel'nichenko, Galina Afanas'evna , Lila, Anurag Ranjan , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.1344 Get It

Abstract Disclosure: S.R. Chacko: None. C.A. Villavicencio Torres: None. K. Yu: None. S.G. Waguespack: None. L. Lu: None. Z. Belaya: None. T. Bandgar: None. A. Sada: None. O. Ragnarsson: None. B. Altieri: None. A. Newman: None. P. Vibhatavata: None. M. Tóth: None. E.V. Varlamov: None. C. Badiu: None. A. Paissan: None. M. St-Jean: None. H. Falhammar: None. N. Imamudeen: None. L. Haberbosch: None. M. Bobrowicz: None. A. Tabarin: None. R. Shah: None. M.R. Gadelha: None. A. Peersen: None. W.F. Young: None. J. Kaplan: None. J. Varghese: None. M.A. Habra: None. O. Golounina: None. G.A. Melnichenko: None. A.R. Lila: None. C. Yamichannaiah: None. I. Bancos: None. Context: Cushing syndrome (CS) due to ectopic ACTH secretion (EAS) is a rare condition, associated with severe hypercortisolism and consequent morbidity and mortality. Its varied and often emergent presentation make diagnosis and treatment challenging. Objectives: 1.Characterize clinical and biochemical presentation of EAS. 2.Describe the scope of hypercortisolism-related complications, overall and CS-specific mortality. 3.Identify factors associated with CS-specific mortality. Methods: We conducted a multicenter retrospective cohort study in patients with EAS at 37 centers. Outcomes were clinical/biochemical severity scores, complications, overall and CS-specific mortality. Results: In 1053 patients [median age at diagnosis 52 years (IQR 37-64), 57% women], metastatic disease was present at diagnosis in 585 (56%). The most common sources of EAS were bronchial neuroendocrine neoplasm (NEN) (304, 29%), pancreatic NEN (114, 11%) and small cell lung carcinoma (114, 11%), with the source of EAS being occult in 192 (18%). Clinical and biochemical severity scores were severe in 475 (45%) and 873 patients (92%) respectively. Hypokalemia was present in 819 patients (78%) in the year prior to diagnosis. Of 342 patients (32%) who had IPSS, 301 (88%) suggested an ectopic source, 7 (2%) a pituitary source, and 23 (7%) were non-diagnostic. Of 595 patients who had both functional and cross-sectional imaging, discordant findings were seen in 122 (21%), concordant lesion was seen on both in 326 (55%), and no lesion in 147 (25%). Of those with discordant results, cross-sectional imaging was accurate in 66 (54%) and functional imaging in 56 (46%).Management included medical therapy alone in 237 (23%), surgical excision of the source of EAS in 158 (15%), bilateral adrenalectomy in 77 (7%) and multimodal therapies in 498 patients (47%). Complications within 5 years after diagnosis included hospitalization related to CS or its therapy in 351 (33%), infection in 337 (32%), thromboembolic event in 102 (10%), cardiovascular event in 83 (8%) and cerebrovascular event in 27 (3%). During a median follow-up of 35 months (IQR 20-122) from CS diagnosis, death occurred in 462 patients (44%), with the cause of death related to CS in 149 (14%). CS-specific mortality was higher in metastatic compared with non-metastatic disease (19% vs. 7%, P&lt;0.001). On multivariable analysis of age, sex, clinical and biochemical severity, older age (HR 1.03, 95% CI: 1.02-1.04) and lower clinical severity score (HR 0.97, 95% CI: 0.94-0.99), were associated with higher CS-specific mortality. Conclusion: Our interim analysis, the largest worldwide, found that most patients with EAS had severe hypercortisolism and hypokalemia. Metastatic disease was present in 56%, and the source of EAS was occult in 18%. CS-related death occurred in 14%, emphasizing the need for urgent management. Presentation: Monday, July 14, 2025
Mobility Functional Status Ascertainment in Electronic Health Records using Large Language Models
Garg, Muskan, Jia, Heling , Sohn, Sunghwan , St Sauver, Jennifer, Pagali, Sandeep R. , Liu, Xingyi , Garg, Muskan , Sauver, Jennifer L. St.

Mayo Clinic

No container title available | July 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7104310/v1 | PMID 40766236 Get It

Abstract With global aging, assessing functional status is vital for precision medicine. Electronic Health Records (EHRs), particularly unstructured data, hold abundant information on patient mobility. This study explores using Large Language Models (LLMs) to extract and standardize mobility status from unstructured EHR data (i.e., clinical notes). We annotated 600 clinical notes from three health care institutions located in southeastern Minnesota and west-central Wisconsin, focusing on expressions of mobility and associated impairment. Leveraging the open-source Llama 3 model, we tested various prompting strategies—including zero-shot, few-shot, and task decomposition—and evaluated their performance. Error analysis showed that while the model sometimes inferred impairments without explicit evidence, most errors were clinically reasonable, often reflecting borderline or ambiguous cases. While considering reasonable inference as correct, at the patient-level, Mobility Extraction achieves a micro-average accuracy of 0.952 with an F1-score of 0.962, and Impairment Classification produces a micro-average accuracy of 0.912 and an F1-score of 0.948. A local, deterministic setup improved trustworthiness by ensuring consistent outputs, safeguarding privacy, and demonstrating cross-institution generalizability. These findings highlight the feasibility of LLM-based solutions for extracting mobility functional status from unstructured EHR data, supporting both clinical applications and research.
Neoadjuvant pembrolizumab in combination with dabrafenib and trametinib (DTP) for BRAF V600E-mutated anaplastic thyroid cancer ( BRAF m-ATC): A multicenter phase 2 trial.
Zafereo, Mark , Busaidy, Naifa L. , Dadu, Ramona , Li, Xu , Geiger, J.L. , Kerrigan, Kathleen , Khan, Saad A. , Moore, Eric J. , Scharpf, Joseph , Wang, Jennifer Rui , Iyer, Priyanka , Waguespack, Steven G. , Maniakas, Anastasios , Banuchi, Victoria , Lai, Stephen Y. , Chinn, Steven Bennett , Ryder, Mabel , Worden, Francis P. , Williams, Michelle D. , Cabanillas, Maria E.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 6008-6008

10.1200/jco.2025.43.16_suppl.6008 Get It

6008 Background: ATC patients present with advanced, often surgically unresectable disease with historically dismal prognosis. Median PFS and OS of DT without pembrolizumab were 6.7 and 13.5 months, respectively, in the ROAR trial. Neoadjuvant DTP achieved locoregional control without radical surgery in a retrospective series of BRAF m-ATC patients, providing rationale to evaluate efficacy and safety in a phase 2 prospective trial. Methods: In this single-arm multicenter phase 2 trial, patients with BRAF m-ATC stage IVB/IVC were enrolled in 5 US centers. Following a 3-6 week run-in with D (150 mg BID) and T (2 mg daily), P (200 mg Q3W) was added, with restaging every three (21-day) cycles. Post-operatively, patients continued P (or DTP) with radiotherapy or transitioned directly to adjuvant DTP (up to 26 cycles). Primary endpoints included R0/R1 resection rate (historically 5%) and overall survival (OS). Secondary endpoints included RECIST 1.1 response after DTP and progression-free survival (PFS). Results: Between 9/2021-1/2025, 42 patients were enrolled; 36 are included in the current analysis (3 not evaluable, 3 pending surgery) (Table). Patients received median 4 (range: 2-7) neoadjuvant DTP cycles, with 26 (72%) achieving radiographic PR/CR. 30 patients (83%) had surgery after neoadjuvant DTP, achieving R0/R1 resection in 29/30 (97%). Mean surgical morbidity score (0-4 scale, 4=unresectable) improved from 3.3 to 1.6 after DTP (p<0.01). Complete ATC pathologic response occurred in 20/30 patients (67%), while 10/30 (33%) had residual ATC in the surgical specimen. Postoperatively, 11/30 (37%) received adjuvant neck radiation, and 28/36 (78%) completed a median of 11 (range: 1-26) adjuvant DTP cycles. With median follow up 18 months, 15/36 (42%) patients died. Median OS was 20 months (95% CI: 12.6-NR); 1- and 2-year OS were 71% and 48%. Complete pathologic responders had better 2-year OS than those with residual ATC (69% vs. 22%, p=0.02). Median PFS was 13.9 months (95% CI, 7.5-NR); 1- and 2-year PFS were 57% and 36%. Grade 5 adverse events occurred in 8 patients (22%), including one possible (duodenal perforation), one probable (kidney injury with sepsis), and 6 unlikely/unrelated treatment-related deaths. Conclusions: Neoadjuvant DTP enables surgical resection in BRAF m-ATC compared with historical controls, and leads to improved PFS and OS. This approach should now be considered a standard of care for BRAF m-ATC. Clinical trial information: NCT04675710 . Total N=36 Age (y), median (range) 67 (46-86) Stage IVB/IVC, n (%) 15 (42%)/21 (58%) Best RECIST response neoadjuvant phase, n (%) CR 2 (6%) PR 24 (67%) SD 6 (17%) PD 4 (11%) Percent change target lesion diameter, mean (95% CI) -44% (-54%, -34%) Surgical morbidity score change, mean (95% CI) -1.7 (-2.1, -1.3)
Effect of Reiki on Measures of Well-Being in Low-Income Patients with Mental Health Diagnoses
Prasad, Kavita, Drost, M., Baldwin, Ann L. , Soderlind, Jennifer N., Croghan, Ivana T. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , St Sauver, Jennifer, Drost, Mitchell S, Croghan, Ivana T , Wahner-Roedler, Dietlind L , Bauer, Brent A , Dyer, Natalie L. , Sauver, Jennifer L. St. , Drost, Mitchell S., Prasad, Vikas, Hassan, Ahmed Nabeel

Mayo Clinic

Global Advances in Integrative Medicine and Health | March 4, 2025 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/27536130251323581 | PMID 40034577 Get It

Background More than 1 in 5 US adults live with mental illness. Novel therapies as complements to standard therapies are needed to improve patient well-being. Reiki is a biofield therapy that may improve well-being in mental health. Objective The primary aim of this study was to evaluate the feasibility of providing Reiki at a behavioral health clinic serving a low-income population. The secondary aim was to evaluate outcomes in terms of patients’ symptoms, emotions, and feelings before and after Reiki. Methods This was a mixed-methods, feasibility pilot study with a pre-post experimental design. Reiki was offered to adult outpatients at a community behavioral health center in Rochester, Minnesota. Patients with a stable mental health diagnosis seen between July 22, 2021, and May 18, 2023, completed surveys before and after the Reiki intervention and provided qualitative feedback. Patients were asked to report their ratings of pain, anxiety, fatigue, and feelings (eg, happy, calm) on 0- to 10-point numeric rating scales. Data were analyzed with Wilcoxon signed rank tests. Results Among 91 patients who completed a Reiki session during the study period, 74 (81%) were women. Major depressive disorder (71%), posttraumatic stress disorder (47%), and generalized anxiety disorder (43%) were the most common diagnoses. The study was feasible in terms of recruitment, retention, data quality, acceptability, and fidelity of the intervention. Patient ratings of pain, fatigue, anxiety, stress, sadness, and agitation were significantly lower, and ratings of happiness, energy levels, relaxation, and calmness were significantly higher after a single Reiki session. Conclusion The results of this study suggest that Reiki is feasible and could be fit into the flow of clinical care in an outpatient behavioral health clinic. It improved positive emotions and feelings and decreased negative measures. Implementing Reiki in clinical practice should be further explored to improve mental health and well-being.
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Cesano, Alessandra, Augustin, Ryan C. , Barrea, Luigi , Carturan, Alberto , Ho, Winson S. , Kather, Jakob Nikolas , Lu, Rongze O., McQuade, Jennifer L. , Najjar, Yana G. , Shen, Rhine R. , Warner, Allison Betof , Warren, Sarah H. , Ziv, Elad , Marincola, Francesco M, Augustin, Ryan, Carturan, Alberto , Najjar, Yana G , Ruella, Marco , Betof Warner, Allison , Warren, Sarah , Ziv, Elad , Bedognetti, Davide , Bruno, Tullia Carmela , Hammer, Christian , Kather, Jakob Nikolas , Kirchhoff, Tomas , Pietrobon, Violena , Ruella, Marco , Soldati, Laura , Spencer, Christine N. , Marincola, Francesco M.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 17, 2025 | Volume: 13 | Issue: 1 | Pages: e008876

10.1136/jitc-2024-008876 | PMID 39824527 Get It

Cancer immunotherapy—including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)—has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with cancer do not benefit from the rapidly evolving improvements in the understanding of principal mechanisms determining cancer immune responsiveness (CIR); including patient-specific genetically determined and acquired factors, as well as intrinsic cancer cell biology. Though CIR is multifactorial, fundamental concepts are emerging that should be considered for the design of novel therapeutic strategies and related clinical studies. Recent advancements as well as novel approaches to address the limitations of current treatments are discussed here, with a specific focus on ICI and ACT.
The Influence of Body Mass Index on Biomarkers of Cellular Senescence in Older Adults
Fielding, Roger A. , Atkinson, Elizabeth J. , White, Thomas A. , McGree, Michaela E. , Weston, Susan A., St Sauver, Jennifer, Atkinson, Elizabeth , McGree, Michaela, Weston, Susan, Palmer, Allyson K. , Sauver, Jennifer L. St. , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | October 24, 2024 | Volume: 80 | Issue: 4 | Pages: No page available

10.1093/gerona/glae251 | PMID 39447036 Get It

Abstract Obesity accelerates the onset and progression of age-related conditions. In preclinical models, obesity drives cellular senescence, a cell fate that compromises tissue health and function, in part through a robust and diverse secretome. In humans, components of the secretome have been used as senescence biomarkers that are predictive of age-related disease, disability, and mortality. Here, using biospecimens and clinical data from two large and independent cohorts of older adults, we tested the hypothesis that the circulating concentrations of senescence biomarkers are influenced by body mass index. After adjusting for age, sex, and race, we observed significant increases in activin A, Fas, MDC, PAI1, PARC, TNFR1, and VEGFA, and a significant decrease in RAGE, from normal weight, to overweight, to obesity body mass index categories by linear regression in both cohorts (all p &lt; .05). These results highlight the influence of body mass index on circulating concentrations of senescence biomarkers.
Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations
Samadder, N. Jewel , Gay, E. Greer , Lindpere, Vanda , Bublitz, Michelle L. , Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Klee, Eric W. , Larson, Nicholas B. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa , McAllister, Tammy M., Walker, T'Nita S., Klint, Margaret A., Presutti, R. John , Summer-Bolster, Jolene M., Gay, Emily , Klee, Eric W , Larson, Nicholas B , Kruisselbrink, Teresa M, Bidwell, Jessa S , Anderson, Jennifer L. , Kunze, Katie L , Golafshar, Michael A. , Presutti, Richard J , Bobo, William V. , Sekulic, Aleksander , Willman, Cheryl , Lazaridis, Konstantinos N , Lindpere, Vanda , Vierkant, Robert A. , Anderson, Jennifer L., Kunze, Katie L. , Klint, Margaret, Willman, Cheryl L. , Lazaridis, Konstantinos N.

Mayo Clinic

JCO Precision Oncology | July 16, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.24.00106 | PMID 39013133 Get It

PURPOSE The autosomal dominant cancer predisposition disorders hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) are genetic conditions for which early identification and intervention have a positive effect on the individual and public health. The goals of this study were to determine whether germline genetic screening using exome sequencing could be used to efficiently identify carriers of HBOC and LS. METHODS Participants were recruited from three geographically and racially diverse sites in the United States (Rochester, MN; Phoenix, AZ; Jacksonville, FL). Participants underwent Exome+ sequencing (Helix Inc, San Mateo, CA) and return of results for specific genetic findings: HBOC ( BRCA1 and BRCA1) and LS ( MLH1, MSH2, MSH6, PMS2, and EPCAM). Chart review was performed to collect demographics and personal and family cancer history. RESULTS To date, 44,306 participants have enrolled in Tapestry. Annotation and interpretation of all variants in genes for HBOC and LS resulted in the identification of 550 carriers (prevalence, 1.24%), which included 387 with HBOC (27.2% BRCA1, 42.8% BRCA2) and 163 with LS (12.3% MSH6, 8.8% PMS2, 4.5% MLH1, 3.8% MSH2, and 0.2% EPCAM). More than half of these participants (52.1%) were newly diagnosed carriers with HBOC and LS. In all, 39.2% of HBOC/LS carriers did not satisfy National Comprehensive Cancer Network (NCCN) criteria for genetic evaluation. NCCN criteria were less commonly met in underrepresented minority populations versus self-reported White race (51.5% v 37.5%, P = .028). CONCLUSION Our results emphasize the need for wider utilization of germline genetic sequencing for enhanced screening and detection of individuals who have LS and HBOC cancer predisposition syndromes.
Primary human papillomavirus testing by clinician- versus self-collection: Awareness and acceptance among cervical cancer screening-eligible women
MacLaughlin, Kathy L. , Jenkins, Gregory D. , Fan, Chun , Miller, Nathaniel E. , Meyer, Amanda F. , Jacobson, Robert M. , St Sauver, Jennifer, Miller, Nathaniel E , Jacobson, Robert M , Sauver, Jennifer L. St. , Rutten, Lila J. Finney

Mayo Clinic

Journal of Medical Screening | June 13, 2024 | Volume: 31 | Issue: 4 | Pages: 223-231

10.1177/09691413241260019 | PMID 38869176 Get It

Objectives Primary human papillomavirus (HPV) testing by clinician-collection is endorsed by U.S. guideline organizations for cervical cancer screening, but uptake remains low and insights into patients’ understanding are limited. This study aims to primarily address patient awareness of primary HPV screening by clinician-collection and acceptance of primary HPV screening by clinician- and self-collection, and secondarily assess factors associated with awareness and acceptance. Setting Primary care practices affiliated with an academic medical center. Methods A cross-sectional survey study of screening-eligible women aged 30–65 years was conducted to assess awareness and acceptability of primary HPV screening. We analyzed bivariate associations of respondent characteristics with awareness of primary HPV screening by clinician-collection, willingness to have clinician- or self-collected primary HPV testing, and reasons for self-collection preference. Results Respondents (n = 351; response rate = 23.4%) reported cervical cancer screening adherence of 82.8% but awareness of clinician-collected primary HPV as an option was low (18.9%) and only associated with HPV testing with recent screening ( p = 0.003). After reviewing a description of primary HPV screening, willingness for clinician-collected (81.8%) or home self-collected (76.1%) HPV testing was high, if recommended by a provider. Acceptability of clinician-collected HPV testing was associated with higher income ( p = 0.009) and for self-collection was associated with higher income ( p = 0.002) and higher education ( p = 0.02). Higher education was associated with reporting self-collection as easier than clinic-collection ( p = 0.02). Women expected self-collection to be more convenient (94%), less embarrassing (85%), easier (85%), and less painful (81%) than clinician-collection. Conclusions Educational interventions are needed to address low awareness about the current clinician-collected primary HPV screening option and to prepare for anticipated federal licensure of self-collection kits. Informing women about self-collection allows them to recognize benefits which could address screening barriers.
A taxonomy for advancing systematic error analysis in multi-site electronic health record-based clinical concept extraction
Fu, Sunyang , Wang, Liwei , Zong, Nansu , Zhou, Sicheng , Zhang, Rui , Li, Chenyu , Wang, Yanshan , Sohn, Sunghwan , Zhang, Rui , Li, Chenyu , St Sauver, Jennifer, Liu, Hongfang , He, Huan , Fu, Sunyang , Wang, Yanshan , He, Huan , Wen, Andrew , Kumari, Anamika , Liu, Feifan , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | April 19, 2024 | Volume: 31 | Issue: 7 | Pages: 1493-1502

10.1093/jamia/ocae101 | PMID 38742455 Get It

Abstract Background Error analysis plays a crucial role in clinical concept extraction, a fundamental subtask within clinical natural language processing (NLP). The process typically involves a manual review of error types, such as contextual and linguistic factors contributing to their occurrence, and the identification of underlying causes to refine the NLP model and improve its performance. Conducting error analysis can be complex, requiring a combination of NLP expertise and domain-specific knowledge. Due to the high heterogeneity of electronic health record (EHR) settings across different institutions, challenges may arise when attempting to standardize and reproduce the error analysis process. Objectives This study aims to facilitate a collaborative effort to establish common definitions and taxonomies for capturing diverse error types, fostering community consensus on error analysis for clinical concept extraction tasks. Materials and Methods We iteratively developed and evaluated an error taxonomy based on existing literature, standards, real-world data, multisite case evaluations, and community feedback. The finalized taxonomy was released in both .dtd and .owl formats at the Open Health Natural Language Processing Consortium. The taxonomy is compatible with several different open-source annotation tools, including MAE, Brat, and MedTator. Results The resulting error taxonomy comprises 43 distinct error classes, organized into 6 error dimensions and 4 properties, including model type (symbolic and statistical machine learning), evaluation subject (model and human), evaluation level (patient, document, sentence, and concept), and annotation examples. Internal and external evaluations revealed strong variations in error types across methodological approaches, tasks, and EHR settings. Key points emerged from community feedback, including the need to enhancing clarity, generalizability, and usability of the taxonomy, along with dissemination strategies. Conclusion The proposed taxonomy can facilitate the acceleration and standardization of the error analysis process in multi-site settings, thus improving the provenance, interpretability, and portability of NLP models. Future researchers could explore the potential direction of developing automated or semi-automated methods to assist in the classification and standardization of error analysis.